Identification of breast cancer biomarkers in transgenic mouse models: A proteomics approach

Proteomics - Clinical Applications

Volumn 4, Issue 6-7, 2010, Pages 603-612

  Rodenburg, Wendy ^a   Pennings, Jeroen L A ^a   van Oostrom, Conny T M ^a   Roodbergen, Marianne ^a   Kuiper, Raoul V ^a,b   Luijten, Mirjam ^a   de Vries, Annemieke ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Faculty of Veterinary Medicine   (Netherlands)

Author keywords

Biomarker; Breast cancer; Multi analyte profiling; Transgenic mouse model

Indexed keywords

C REACTIVE PROTEIN; CD40 ANTIGEN; CYSTATIN C; ESTROGEN RECEPTOR; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOPONTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P53; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE MARKER; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD40; CYSTATIN C; FEMALE; INTERLEUKIN-18; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; OSTEOPONTIN; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

MUS; MUS MUSCULUS;

EID: 77955793363     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900175     Document Type: Article

References (46)

1. Bray, F., McCarron, P., Parkin, D. M., The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004, 6, 229-239.
2. Elmore, J. G., Armstrong, K., Lehman, C. D., Fletcher, S. W., Screening for breast cancer. JAMA 2005, 293, 1245-1256.
3. Cho, W. C., Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer 2007, 6, 25.
4. Levenson, V. V., Biomarkers for early detection of breast cancer: what, when, and where? Biochim. Biophys. Acta 2007, 1770, 847-856.
5. Hanash, S. M., Pitteri, S. J., Faca, V. M., Mining the plasma proteome for cancer biomarkers. Nature 2008, 452, 571-579.
6. Ludwig, J. A., Weinstein, J. N., Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005, 5, 845-856.
7. Kulasingam, V., Diamandis, E. P., Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 2008, 5, 588-599.
8. Frese, K. K., Tuveson, D. A., Maximizing mouse cancer models. Nat. Rev. Cancer 2007, 7, 645-658.
9. Gopinathan, A., Tuveson, D. A., The use of GEM models for experimental cancer therapeutics. Dis. Model Mech. 2008, 1, 83-86.
10. Hung, K. E., Faca, V., Song, K., Sarracino, D. A. et al., Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev. Res. 2009, 2, 224-233.
11. Whiteaker, J. R., Zhang, H., Zhao, L., Wang, P. et al., Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J. Proteome Res. 2007, 6, 3962-3975.
12. Faca, V. M., Song, K. S., Wang, H., Zhang, Q. et al., A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 2008, 5, e123.
13. Pitteri, S. J., Faca, V. M., Kelly-Spratt, K. S., Kasarda, A. E. et al., Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J. Proteome Res. 2008, 7, 1481-1489.
14. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., Leder, P., Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54, 105-115.
15. Wijnhoven, S. W., Zwart, E., Speksnijder, E. N., Beems, R. B. et al., Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res. 2005, 65, 8166-8173.
16. Mor, G., Visintin, I., Lai, Y., Zhao, H. et al., Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 7677-7682.
17. Breiman, L., Random forests. Machine Learning 2001, 45, 5-32.
18. Liaw, A. W., M, Classification and regression by random forests. R News 2002, 2, 18-22.
19. Barrett, J. H., Cairns, D. A., Application of the random forest classification method to peaks detected from mass spectrometric proteomic profiles of cancer patients and controls. Stat. Appl. Genet. Mol. Biol. 2008, 7, Article 4.
20. Diaz-Uriarte, R., Alvarez de Andres, S., Gene selection and classification of microarray data using random forest. BMC Bioinformatics 2006, 7, 3.
21. Rousseeuw, P., Leroy, A. M., Robust Regression and Outlier Detection, Wiley, New York 1987.
22. Vapnik V., Statistical Learning Theory, Wiley, New York 1998.
23. Zhang, X., Lu, X., Shi, Q., Xu, X. Q. et al., Recursive SVM feature selection and sample classification for massspectrometry and microarray data. BMC Bioinformatics 2006, 7, 197.
24. Wijnhoven, S. W., Speksnijder, E. N., Liu, X., Zwart, E. et al., Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Res. 2007, 67, 4648-4656.
25. Lin, E. Y., Jones, J. G., Li, P., Zhu, L. et al., Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 2003, 163, 2113-2126.
26. Hoeflich, A., Reisinger, R., Lahm, H., Kiess, W. et al., Insulinlike growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res. 2001, 61, 8601-8610.
27. Perry, N., Broeders, M., de Wolf, C., Tornberg, S., et al., European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition - summary document. Ann. Oncol. 2008, 19, 614-622.
28. Krupke, D. M., Begley, D. A., Sundberg, J. P., Bult, C. J., Eppig, J. T., The Mouse Tumor Biology database. Nat. Rev. Cancer 2008, 8, 459-465.
29. Kelly-Spratt, K. S., Kasarda, A. E., Igra, M., Kemp, C. J., A mouse model repository for cancer biomarker discovery. J. Proteome Res. 2008, 7, 3613-3618.
30. Carlsson, A., Wingren, C., Ingvarsson, J., Ellmark, P. et al., Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur. J. Cancer 2008, 44, 472-480.
31. Kim, B. K., Lee, J. W., Park, P. J., Shin, Y. S. et al., The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res. 2009, 11, R22.
32. Rittling, S. R., Chambers, A. F., Role of osteopontin in tumour progression. Br. J. Cancer 2004, 90, 1877-1881.
33. Johnston, N. I., Gunasekharan, V. K., Ravindranath, A., O'Connell, C. et al., Osteopontin as a target for cancer therapy. Front. Biosci. 2008, 13, 4361-4372.
34. Tuck, A. B., Chambers, A. F., Allan, A. L., Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J. Cell. Biochem. 2007, 102, 859-868.
35. Cox, J. L., Cystatins and cancer. Front. Biosci. 2009, 14, 463-474.
36. Vigneswaran, N., Wu, J., Muller, S., Zacharias, W. et al., Expression analysis of cystatin C and M in laser-capture microdissectioned human breast cancer cells--a preliminary study. Pathol. Res. Pract. 2005, 200, 753-762.
37. Yano, M., Hirai, K., Naito, Z., Yokoyama, M. et al., Expression of cathepsin B and cystatin C in human breast cancer. Surg. Today 2001, 31, 385-389.
38. Hung, K. E., Kho, A. T., Sarracino, D., Richard, L. G. et al., Mass spectrometry-based study of the plasma proteome in a mouse intestinal tumor model. J. Proteome Res. 2006, 5, 1866-1878.
39. Vonderheide, R. H., Prospect of targeting the CD40 pathway for cancer therapy. Clin. Cancer Res. 2007, 13, 1083-1088.
40. Park, S., Cheon, S., Cho, D., The dual effects of interleukin-18 in tumor progression. Cell. Mol. Immunol. 2007, 4, 329-335.
41. Harvey, S., Kohga, S., Sait, S. N., Markus, G. et al., Co-expression of urokinase with haptoglobin in human carcinomas. J. Surg. Res. 2009, 152, 189-197.
42. Smeets, M. B., Fontijn, J., Kavelaars, A., Pasterkamp, G., De Kleijn, D. P., The acute phase protein haptoglobin is locally expressed in arthritic and oncological tissues. Int. J. Exp. Pathol. 2003, 84, 69-74.
43. Abd Hamid, U. M., Royle, L., Saldova, R., Radcliffe, C. M. et al., A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008, 18, 1105-1118.
44. Abdullah, M., Schultz, H., Kahler, D., Branscheid, D. et al., Expression of the acute phase protein haptoglobin in human lung cancer and tumor-free lung tissues. Pathol. Res. Pract. 2009, 205, 639-647.
45. Hamrita, B., Chahed, K., Trimeche, M., Guillier, C. L. et al., Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas. Clin. Chim. Acta 2009, 404, 111-118.
46. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T. et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98, 10869-10874.